Experiment assessment of mass effects in the rat_ implications for small animal PET imaging

Repositorio e-Archivo

Mostrar el registro sencillo del ítem

dc.contributor.author Jagoda, E. M.
dc.contributor.author Vaquero López, Juan José
dc.contributor.author Seidel, Jürgen
dc.contributor.author Green, Michael V.
dc.contributor.author Eckelman, William C.
dc.date.accessioned 2012-06-19T10:14:51Z
dc.date.available 2012-06-19T10:14:51Z
dc.date.issued 2004-08
dc.identifier.bibliographicCitation Nuclear Medicine and Biology, vol. 31, n. 6, aug. 2004. Pp. 771-779
dc.identifier.issn 0969-8051
dc.identifier.uri http://hdl.handle.net/10016/14598
dc.description.abstract In vivo imaging using positron emission tomography (PET) is important in the development of new radiopharmaceuticals in rodent animal models for use as biochemical probes, diagnostic agents, or in drug development. We have shown mathematically that, if small animal imaging studies in rodents are to have the same “quality” as human PET studies, the same number of coincidence events must be detected from a typical rodent imaging “voxel” as from the human imaging voxel. To achieve this using the same specifi activity preparation, we show that roughly the same total amount of radiopharmaceutical must be given to a rodent as to a human subject. At high specifi activities, the mass associated with human doses, when administered to a rodent, may not decrease the uptake of radioactivity at non saturable sites or sites where an enzyme has a high capacity for a substrate. However, in the case of binding sites of low density such as receptors, the increased mass injected could saturate the receptor and lead to physiologic effects and non-linear kinetics. Because of the importance of the mass injected for small animal PET imaging, we experimentally compared high and low mass preparations using ex vivo biodistribution and phosphorimaging of three compounds: 2-fluoro-2-deoxyglucos (FDG), 6-fluoro-L-metatyrosin (FMT) and one receptor-directed compound, the serotonin 5HT1A receptor ligand, trans-4-fluoro-N-{2-[4-(2-methoxylphenyl piperazino]ethyl}-N-(2- pyridyl) cyclohexane- carboxamide (FCWAY). Changes in the mass injected per rat did not affect the distribution of FDG, FMT, and FCWAY in the range of 0.6 –1.9 nmol per rat. Changes in the target to nontarget ratio were observed for injected masses of FCWAY in the range of 5–50 nmol per rat. If the specifi activity of such compounds and/or the sensitivity of small animal scanners are not increased relative to human studies, small animal PET imaging will not correctly portray the “true” tracer distribution. These difficultie will only be exacerbated in animals smaller than the rat, e.g., mice.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Elsevier
dc.rights © Elsevier
dc.subject.other Animal imaging
dc.subject.other PET
dc.subject.other FDG
dc.subject.other FMT
dc.subject.other FCWAY
dc.title Experiment assessment of mass effects in the rat_ implications for small animal PET imaging
dc.type article
dc.description.status Publicado
dc.relation.publisherversion http://dx.doi.org/10.1016/j.nucmedbio.2004.04.003
dc.subject.eciencia Biología y Biomedicina
dc.identifier.doi 10.1016/j.nucmedbio.2004.04.003
dc.rights.accessRights openAccess
dc.type.version acceptedVersion
dc.identifier.publicationfirstpage 771
dc.identifier.publicationissue n. 6
dc.identifier.publicationlastpage 779
dc.identifier.publicationtitle Nuclear Medicine and Biology
dc.identifier.publicationvolume vol. 31
 Find Full text

Ficheros en el ítem

*Click en la imagen del fichero para previsualizar.(Los elementos embargados carecen de esta funcionalidad)


Este ítem aparece en la(s) siguiente(s) colección(es)

Mostrar el registro sencillo del ítem